Polly Murphy

Director/Board Member chez CELCUITY INC.

Fortune : 202 112 $ au 31/03/2024

59 ans

Health Technology

Consumer Services

Profil

Polly A.
Murphy is an Independent Director at Atea Pharmaceuticals, Inc., Celcuity, Inc., and Chief Business Officer at UroGen Pharma Ltd.
She previously worked as Vice President-Commercial Development at Pfizer Inc. from 2019 to 2020 and as Senior VP-Business & Scientific Services at The Scripps Research Institute from 2005 to 2008.
Murphy holds a doctorate from Iowa State University and an MBA from Nova Southeastern University, Inc.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
CELCUITY INC. 0,02%	15/05/2023	5 000 ( 0,02% )	108 000 $	31/03/2024
ATEA PHARMACEUTICALS, INC. 0,03%	16/06/2023	23 295 ( 0,03% )	94 112 $	31/03/2024

Postes actifs de Polly Murphy

Sociétés	Poste	Début
UROGEN PHARMA LTD.	Corporate Officer/Principal	09/09/2020
ATEA PHARMACEUTICALS, INC.	Director/Board Member	01/08/2020
CELCUITY INC.	Director/Board Member	12/09/2022

Tous les postes actifs de Polly Murphy

Anciens postes connus de Polly Murphy

Sociétés	Poste	Fin
PFIZER, INC.	Corporate Officer/Principal	01/08/2020
The Scripps Research Institute The Scripps Research Institute Other Consumer ServicesConsumer Services The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California.	Corporate Officer/Principal	01/08/2008